Tag Archive for: Roche

In future, gene vectors for novel gene therapies will be developed and produced for clinical trials on an industrial scale by around 100 employees in the new gene therapy development centre at Roche in Penzberg, which covers around 2,500 square metres. © Roche

Basel-headquartered Roche AG has inaugurated a brand new €90m gene therapy development centre in Penzberg near Munich.

© Freenome Inc

Multi-omics liquid biospy specialist Freenome Inc. has baged US$254m in a financing round led by Roche AG to fund early cancer detection in 6,200 patients using its AI-guided cancer detection platform.

AC Immune at the EPFL Innovation Park © AC Immune

Genentech, Roche’s US subsidiary, is ending its decades-long collaboration with AC Immune SA after disappointing study results. It has handed the global rights to Crenezumab and Semorinemab back to the Lausanne-based biotech.

EM picture of A. baumannii. © Vader1941 - wikipedia.org

Hoffmann-La Roche AG has published details on the mechanism of action of its Phase I antibiotic Zosurabalpin (RG6006) that kills the carbapenem-resistant bug Acinetobacter baumannii.
.

TLA1 mode of action. In fibrosis, the compound's binding to its receptor induces TGF-beta and IL6 release. © Prometheus Biosciences/MSD

Analysts describe as sporting the €7.1bn for Roche AG’s acquisition of Roivant subsidiary Telavant Holdings.

Alnylam CEO Yvonne-Greenstreet. © Alnylam Pharmaceuticals.jpg

siRNA specialist Alnylam Pharmaceuticals Roche has received US$310m upfront from Swiss Roche AG for the ex-US commercialisation rights of zilebesiran, an new antihypertensive.
T

Roche tower I. © Norbert Aepli, Switzerland

Roche’s bruton’s tyrosine kinas blocker fenebrutinib has met all endpoints in proof-of-concept study with patients suffering from relapsing-remitting multiple sclerosis.

T-Cell-Dendritic-Cell interaction. © Hookipa

HOOKIPA has received a US$10m milestone under its 2022 agreement with Roche to develop an arenaviral immunotherapy for KRAS-mutated cancers.

PD-L1 blocks PD-L1 and B7.1 receptors on T cells thus triggering inactivation of cytotoxic T cells. © Genbentech Inc

Roche AG’s US subsidiary Genentech Inc has withdrawn its checkpoint inhibitor atezolizumab from the market after disappointing results in bladder cancer.

©Roche

Schwan follows Franz, Schinecker follows Schwan.